Marvel Biosciences Corp. (MRVL.V)
Marvel Biosciences Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Calgary, AB, CA. The stock last traded at $0.16, down 3.03% on the session, giving a market capitalisation of $10.1M. Its beta of 0.59 implies it has historically moved less than the broad market.
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
Marvel Biosciences Corp. is most often compared with the following Healthcare names: